DEMINITURE the Paperwork Reduction Act of 1995.	no person	s are required to respond to a collection	Approved for use through 04/30/2003. OMB 065 at and Trademark Office; U.S. DEPARTMENT OF COMM on of information unless it displays a valid OMB control n
		Application Number	10/010,058 RE December 7, 2001 Adams 0007
TRANSMITTAL		Filing Date	December 7, 2001
FORM (to be used for all correspondence after initial filing)		First Named Inventor	Adams OCT
		Art Unit	1614
		Examiner Name	Emily Bernhardt
Total Number of Pages in This Submission		Attorney Docket Number	December 7, 2001 Adams 1614 Emily Bernhardt 20791
	ENCI	OSURES (Check all that	
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s)	F Remar	ssion of Supplemental Information	to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below):
Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53	PTO 144	e with references clied, Search K	eport, and Statement Under 37 CFR § 1.97(e)

CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313 on this date September 26, 2003 Typed or printed Eileen M. Ebel Signature Date September 26, 2003

Date

September 26, 2003

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.





Copy

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Inventor(s) David Reginald Adams, et al.

Group: 1624

Serial No. 10/010,058, filed December 7, 2001

Examiner: Bernhardt, Emily B.

For: **NOVEL PIPERAZINE DERIVATIVES**

RESUBMISSION OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Nutley, New Jersey 07110 Date: September 26, 2003

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The Examiner has indicated in the Action of May 22, 2003 that although a 1449 Form was received by the Examiner, the IDS and the references were not. Applicant hereby resubmits the Supplemental Information Disclosure Statement that had been mailed to the United States Patent and Trademark Office on April 11, 2003

Respectfully Submitted,

Attorney for Applicant

Eileen M. Ebel (Reg. No. 37,316)

340 Kingsland Street

Nutley, New Jersey 07110 Telephone: (973) 235-4391 Telefax: (973) 235-4391

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Inventor(s) David Reginald Adams, et al.

Serial No. 10/010,058, filed December 7, 2001

For: NOVEL PIPERAZINE DERIVATIVES

Group: 1624

Examiner: Bernhardt, Emily B.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Nutley, New Jersey 07110 Date: April 11, 2003

Commissioner for Patents Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.

Documents A7-A9, B11-B12, and C16-C20 listed on Form PTO-1449 are enclosed.

Enclosed is a Search Report, dated January 31, 2003, which was issued by the European International Search Authority in the PCT application.

Abstract No. XP002227537 listed in the Search Report is not provided, as it is the Abstract corresponding to C11 which was previously cited in the Information Disclosure Statement mailed February 27, 2002.

Consideration of all the documents cited on Form PTO-1449 is requested.

Serial No. 10/010,058 Filed: December 7, 2001

A Certificate under 37 C.F.R. § 1.97(e) is enclosed.

Respectfully submitted,

Attorney for Applicant

Eileen M. Ebel

(Reg. No. 37,316) 340 Kingsland Street

Nutley, New Jersey 07110

Telephone: (973) 235-4391 Telefax: (973) 235-2363

129196



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE PROPRIES PATENT AND TRADEMARK OFFICE PATENT AND TRADEMARK OFFICE PROPRIES PATENT AND TRADEMARK OFFICE PROPRIES PATENT AND TRADEMARK OFFICE PROPRIES PATENT AND TRADEMARK OFFICE PATENT AND TRADEMARK OFFICE PATENT AND TRADEMARK OFFICE PATENT AND TRADEMARK OFFICE PATENT PATENT PATENT PATENT PATENT

n le Patent Application

Inventors David Reginald Adams, et al.

Serial No. 10/010,058, filed December 7, 2001

Examiner: Bernhardt, Emily B.

For: NOVEL PIPERAZINE DERIVATIVES

STATEMENT UNDER 37 CFR §1.97(e)

Nutley, New Jersey 07110 Date: April 11, 2003

Commissioner for Patents Washington, D.C. 20231

Sir:

I hereby certify:

That each item of information contained in the enclosed supplemental information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of this supplemental information disclosure statement.

That no item of information contained in the supplemental information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign

Serial No. 10/010,058 Filed: December 7, 2001

application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the statement.

Respectfully submitted,

Attorney for Applicant

Eileen M. Ebel

(Reg. No. 37,316) 340 Kingsland Street

Nutley, NJ 07110

Telephone: (973) 235-4391

Telefax: (973) 235-2363

129249

	DUPLICATE	2
--	-----------	---

Substitute for form 1449A/PTO Complete if Known INFORMATION DISCLOSURE **Application Number** 10/010,058 STATEMENT BY APPLICANT Filing Date December 7, 2001 First Name Inventor David Reginald Adams (Use several sheets if necessary) Group Art Unit 1624 Examiner Name Bernhardt, Emily B. Sheet Attorney Docket Number 20791 ōħ U.S. PATENT DOCUMENTS U.S. Patent Document Name of Patentee or Applicant of Cited Date of Publication Cite Examiner Kind Code² Initials' Document of Cited document No.1 Number (if known) MM-DD-YYYY 3,933,802 Pier Giorgio Ferrini, et al. A7 01-20-1976 Jose Luis Castro Pineiro, et al 5,977,116 **A8** 11-02-1999 A9 5,756,817 Yong Moon Choi, et al 05-26-1998 FOREIGN PATENT DOCUMENTS Date of Publication of Foreign Patent Document Cite Name of Patentee or Cited Document Examiner Office³ Number4 Kind Code⁵ Applicant of Cited Document Initials' MM-DD-YYYY No.1 (if known) FR 2 321 890 04-29-1977 **B11** Synthelabo **B12** FR 2 744 449 Fabre Medicament SA 08-08-1997 Pierre

NON PATENT I ITERATURE DOCUMENTS

		NON PATENT LITERATURE DOCUMENTS \	
Examiner Initials'	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
	C16	Abstract No. XP002227535 for TOLDY, et al., Acta Chimica	
,	ľ	Academiae Scientiarum Hungarica., Vol. 53, pg. 279 (1967)	٠.
	C17	Abstract No. XP002227534 for LARKIN, H., et al., Tetrahedron	
.•		Letters, Vol. 27, No. 24, pgs. 2721-2724 (1986)	
	C18	Abstract No. XP002227536 for AICHER, T., et al., Journal of	
•		Medicinal Chemistry, Vol. 43, No. 2, pgs. 236-249 (2000)	
	C19/	HAYS S.J., et al., Journal of Medicinal Chemistry, American	
•		Chemical Society, Washington, US, Vol. 33, No. 10 pgs. 2916	
		2924 (1990)	
	1		
			1
Examiner Signature	(3)	DATE CONSIDERED	
2.5		CONGIDENCE	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include conv. of this form with next communication to applicant

copy of his form with next communication to applicant.

Unique citation designation number. Applicant is to place a check mark here if English language Translation or abstract is attached.

129193